Literature DB >> 17338442

Mental health services for people with intellectual disability in Israel--a review of options.

Mike Stawski1, Joav Merrick.   

Abstract

Intellectual disability (ID) (often also referred to as "mental retardation," "development disability," "mental handicap," "learning disability" or as "generalized learning difficulties") is common in all countries. Many people with ID suffer from psychiatric/behavioral/emotional disturbances (known as "dual diagnosis"). Specialist psychiatric services are needed to address these problems effectively, but are not currently available in most countries, including Israel. This article sets out to describe the problems, current services in Israel, approaches in other countries and proposed solutions for Israel. We believe it important to enforce laws against discrimination based on disability, to raise the general awareness, knowledge and skills among generic mental health professionals on the topic of intellectual disability by inclusion in university, postgraduate and in-service training curricula, to work towards a form of subspecialty within psychiatry along the lines of the model in the United Kingdom and to establish specialized psychiatric services, possibly functioning as back-up to the generic psychiatric services.

Entities:  

Mesh:

Year:  2006        PMID: 17338442

Source DB:  PubMed          Journal:  Isr J Psychiatry Relat Sci        ISSN: 0333-7308            Impact factor:   0.481


  2 in total

1.  Assessing the need for a specialist service for people with intellectual disabilities and mental health problems living in Israel: a qualitative study.

Authors:  Amanda Sinai; Shirli Werner; Mike Stawski
Journal:  Front Pediatr       Date:  2013-12-19       Impact factor: 3.418

2.  Specialist psychiatric health care utilization among older people with intellectual disability - predictors and comparisons with the general population: a national register study.

Authors:  G Ahlström; A Axmon; M Sandberg; J Hultqvist
Journal:  BMC Psychiatry       Date:  2020-02-17       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.